In8bio publishes novel gamma-delta T cell therapy approach for glioblastoma in Frontiers in Immunology.

In8bio, a clinical-stage biopharmaceutical company, has announced a publication in Frontiers in Immunology that discusses their novel gamma-delta T cell therapy approach for glioblastoma, an aggressive form of brain cancer. While cellular therapies have shown promise in hematologic malignancies, they have faced challenges when applied to solid tumors like GBM due to factors such as rapid tumor growth and antigen heterogeneity. The publication reviews IN8bio's innovative strategy for treating solid tumors.

February 14, 2024
4 Articles

Further Reading